Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Clinical phase I study with one-hour paclitaxel infusion.

Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H.

Ann Oncol. 1998 May;9(5):569-72.

PMID:
9653500
2.

A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.

Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.

Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22.

PMID:
8893894
3.

Phase I study of paclitaxel administered by ten-day continuous infusion.

Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS.

Invest New Drugs. 1998-1999;16(3):237-43.

PMID:
10360603
4.

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, et al.

J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75.

PMID:
7674322
5.

Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial.

Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF, Bamberg M.

Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):691-6.

PMID:
9240634
6.

Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.

Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-40-S15-43.

PMID:
9346221
7.

Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.

Chang AY, Boros L, Asbury R, Hui L, Rubins J.

Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-69-S17-71.

PMID:
9374098
8.

Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.

Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1996 Dec;23(6 Suppl 16):35-41.

PMID:
9007119
9.

Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.

Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, Yamamoto K, Inoue H, Shimizu K.

Anticancer Res. 2002 May-Jun;22(3):1833-8.

PMID:
12168878
10.

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN.

Ann Oncol. 1999 Apr;10(4):403-11.

PMID:
10370782
11.

Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.

Iaffaioli RV, Tortoriello A, Santangelo M, Turitto G, Libutti M, Benassai G, Frattolillo A, Ciccarelli PD, De Rosa P, Crovella F, Carbone I, Barbarisi A.

Clin Oncol (R Coll Radiol). 2000;12(4):251-5.

PMID:
11005695
12.

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.

Socinski MA, Mudd PN Jr, Radomski KM, Steagall A, Lawrence P, Bernard S, Letrent SP, Gonzalez P, Brouwer KL.

Anticancer Drugs. 1998 Aug;9(7):611-9.

PMID:
9773805
13.
14.

A dose escalation study of weekly docetaxel in patients with advanced solid tumors.

Kouroussis C, Agelaki S, Mavroudis D, Souglakos J, Kakolyris S, Kalbakis K, Vardakis N, Reppa D, Hatzidaki D, Samonis G, Georgoulias V.

Cancer Chemother Pharmacol. 2000;46(6):488-92.

PMID:
11138462
15.

Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.

Shepherd FA, Latreille J, Paul K, Eisenhauer E.

Semin Oncol. 1996 Dec;23(6 Suppl 16):84-90.

PMID:
9007130
16.

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.

Choy H, Yee L, Cole BF.

Semin Oncol. 1995 Dec;22(6 Suppl 15):38-44. Review.

PMID:
8643969
17.

Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.

Miglietta L, Marenghi C, Nizzo R, Foglia G, Ragni N, Boccardo F.

Oncology. 2001;60(2):116-22.

PMID:
11244325
18.

Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.

Gatzemeier U, Heckmayer M, Neuhauss R, Schlüter I, von Pawel J, Wagner H, Dreps A.

Semin Oncol. 1995 Dec;22(6 Suppl 15):24-8.

PMID:
8643966
19.

Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.

Hainsworth JD, Raefsky EL, Greco FA.

Cancer J Sci Am. 1995 Nov-Dec;1(4):281-7.

PMID:
9166489
20.

Salvage weekly paclitaxel in recurrent ovarian cancer.

Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-62-S15-67.

PMID:
9346225

Supplemental Content

Support Center